Labuxtinib

Overview

Labuxtinib (EVT-8565072; THB335) is a potent dual inhibitor of c-Kit and PDGFR . Labuxtinib exhibits potent inhibitory activity against wild-type c-Kit ( IC 50 = 0.005 μM). Labuxtinib inhibits SCF -dependent and PDGF -dependent cell proliferation, and blocks the proliferation of cells dependent on c-Kit or PDGFR signaling pathways. In animal models of skin allergy, Labuxtinib depletes skin mast cells and significantly alleviates anaphylactic shock responses. Labuxtinib can be used in research on mast cell-related diseases, respiratory diseases, inflammatory diseases, fibrotic diseases, metabolic diseases, and other related conditions.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-156619
• CAS No.: 1426449-01-5
• Molecular Formula: C20H16FN5O2
• Molecular Weight: 377.37
• Purity: 98.74%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source